Ginseng — research evidence

Evidence summary. Across more than fifty randomized controlled trials reviewed in modern systematic reviews, Panax ginseng shows a small but statistically detectable reduction in fasting blood glucose, a modest signal for cancer-related fatigue, and trivial effects on erectile function below validated minimal clinically important difference thresholds. Evidence for cognitive enhancement in healthy adults remains insufficient; the most rigorous review could not pool data due to heterogeneity. The largest recent meta-analysis of cardiovascular risk factors reports significant improvements in inflammatory, liver-function, and oxidative-stress markers, with no detectable effect on glycemic profile, blood pressure, lipids, adipokines, or heart rate at the headline level. Across indications, the strongest claims are modest, the certainty rating in Cochrane reviews is low to moderate, and trial heterogeneity (extract type, ginsenoside profile, duration < 12 weeks) constrains generalizability. Robustness: low-to-moderate; effect sizes are small where they replicate.

What it is

Ginseng refers to the dried root of Panax ginseng C.A. Meyer (Asian or Korean ginseng), a slow-growing perennial cultivated principally in northeast China and the Korean peninsula. The plant takes four to six years to mature; the harvested root is dried whole (“white ginseng”) or steamed before drying (“red ginseng”), with the latter producing distinct ginsenoside profiles via heat-driven hydrolysis.

The closely related Panax quinquefolius — American ginseng — shares core ginsenoside chemistry but has a different dominant-ginsenoside profile (Rb1-leaning vs. P. ginseng’s relative balance of Rb1 and Rg1) and a different traditional indication (cooling-tonic vs. warming-tonic). This article focuses on P. ginseng; American ginseng is treated as a separate entity. Both are distinct from Panax notoginseng (Tian Qi / San Qi), used principally for hemostasis and circulation.

Standardized extracts in clinical trials are typically specified by total ginsenoside content, most commonly 4–7%. Trials that report only “ginseng” without standardization are common in the older literature and contribute meaningfully to the heterogeneity that limits modern meta-analyses.

Mechanism

Ginsenosides — triterpenoid saponins — are the principal candidate active constituents. More than one hundred have been characterized, with Rb1, Rg1, Rd, Re, Rg3, and the gut-microbiome-generated metabolite Compound K most studied. Mechanistic claims at the receptor level remain contested.

Two pharmacokinetic constraints are central to interpreting clinical efficacy claims. First, intact ginsenosides are poorly absorbed; oral bioavailability of major parent ginsenosides is low.¹² Second, the principal active species reaching systemic circulation are deglycosylated metabolites generated by intestinal microbiota — most notably Compound K, formed from PPD-type ginsenosides — meaning between-subject variability in gut flora drives between-subject variability in pharmacokinetic exposure.¹³ In-vitro mechanistic findings in pure-compound preparations therefore generalize cautiously to oral dosing in humans, where the molecule the receptor encounters is often not the molecule administered.

Documented pharmacological activities in non-clinical models include modulation of insulin signaling, NO-mediated vasodilation, attenuation of pro-inflammatory cytokines, and effects on neurotransmitter systems implicated in mood and cognition. Translation of any single mechanism to the clinical effect sizes observed in human trials is incomplete.³

Evidence

Glycemic control

Across 16 RCTs (n = 770 for fasting blood glucose), ginseng modestly but significantly reduced fasting blood glucose by a mean difference of −0.31 mmol/L (95% CI: −0.59 to −0.03; p = 0.03), corresponding to roughly 5.6 mg/dL.⁴ Effects on glycated hemoglobin, fasting plasma insulin, and HOMA-IR were not significant overall; the abstract reports a between-design heterogeneity statistic (parallel vs. crossover trials) of MD 0.22% (95% CI 0.06–0.37) on HbA1c, but does not unambiguously translate this subgroup difference into a per-arm treatment effect, so a per-arm HbA1c effect is not extracted here. Sixty-seven percent of included trials were shorter than 12 weeks, and most participants had relatively well-controlled baseline glycemia. The authors call for larger, longer trials of standardized preparations.

Cardiovascular risk factors

A 2025 dose-response meta-analysis of 70 RCTs (n = 4,506) found that ginseng supplementation significantly improved inflammatory markers (high-sensitivity C-reactive protein: −0.23, p = 0.002; with dose-response signals on IL-6 and IL-10), liver function (gamma-glutamyl transferase: −0.20, p = 0.015), and oxidative-stress markers (reactive oxygen species: −0.94, p < 0.001; superoxide dismutase: +0.48, p = 0.014; glutathione reductase: +0.90, p = 0.001).⁵ No significant effect was detected on glycemic profile, blood pressure, lipid profile, adipokines, anthropometric indices, or heart rate at the headline level, although dose-response curves were significant for fasting blood glucose, fasting insulin, diastolic blood pressure, and hs-CRP. The headline null on the glycemic panel is in directional tension with the Shishtar review⁴ and likely reflects the inclusion of a wider, more heterogeneous trial set rather than a true contradiction; a head-to-head reconciliation has not been published. Replication across independent populations and longer follow-up remain open.

Fatigue

Three modern meta-analyses converge on a small-to-moderate signal for fatigue reduction, with stronger evidence in cancer-related fatigue (CRF) than in general fatigue.

In a 2016 meta-analysis of 12 RCTs (n = 630 across intervention and placebo), ginseng improved fatigue with a standardized mean difference of 0.34 (95% CI: 0.16–0.52; based on 4 trials with extractable fatigue data); the same review found no association with physical performance enhancement (SMD = −0.01, 95% CI: −0.29 to 0.27; 8 trials).⁶ A 2022 meta-analysis of disease-related fatigue reported a similar directional benefit.⁷ A 2023 review of ginseng and ginseng herbal formulas for fatigue likewise found modest but statistically detectable effect sizes.⁸

In CRF specifically, a 2023 systematic review and meta-analysis of 7 RCTs reported a small reduction in fatigue (SMD = −0.21, 95% CI: −0.42 to 0.00) and small improvements in physical and emotional well-being (SMD = 0.25, 95% CI: 0.09–0.41 and SMD = 0.20, 95% CI: 0.01–0.40 respectively).⁹ All effect sizes are below the threshold typically considered clinically meaningful for individual patients; the CRF literature remains limited by sample sizes and trial heterogeneity in cancer type and chemotherapy regimen.

Cognition

The 2010 Cochrane review of Panax ginseng for cognition identified 9 RCTs but could analyze only 5 due to heterogeneity in outcome measures, trial duration, and dosage.¹⁰ No meta-analysis was possible. The authors concluded that the available evidence does not provide convincing support for cognitive enhancement in healthy persons, and that high-quality evidence in dementia patients does not exist. No serious adverse events were reported. The certainty of evidence is low to insufficient. The review has not been updated since 2010, and individual trials published subsequently have not yet been pooled in an updated Cochrane synthesis at the time of writing.

Erectile dysfunction

The 2021 Cochrane review of ginseng for erectile dysfunction (9 RCTs, n = 587, follow-up ≤ 12 weeks) reported effect sizes on validated instruments that fall below the minimal clinically important difference (MCID) thresholds for those instruments.¹¹ On the IIEF-5, ginseng vs. placebo: MD 2.39 (95% CI: 0.89–3.88; moderate-certainty), against an MCID of 5. On the IIEF-15, MD 3.52 (95% CI: 1.79–5.25; low-certainty), against an MCID of 4. Self-reported ability to have intercourse showed a larger relative effect (RR 2.55, 95% CI: 1.76–3.69; low-certainty), but the authors’ overall conclusion remains that ginseng “may only have trivial effects on erectile function or satisfaction with intercourse.” No head-to-head trials against PDE5 inhibitors exist. A 2018 broader herbal-supplements meta-analysis reached similar trivial-to-small conclusions for ginseng among ED interventions.¹² An earlier 2008 systematic review on Korean red ginseng — frequently cited in primary clinical literature — reported a more positive directional signal but with substantially weaker methodology than the Cochrane review.¹³

Cross-indication summaries

Two broader systematic reviews of Panax ginseng RCTs (a 2013 review of the international literature¹⁴ and a 2013 review of Korean-language RCTs¹⁵) document the breadth of indications studied (cognition, glycemic control, fatigue, sexual function, immune endpoints, sport performance, mood) without finding any indication where evidence is unambiguously strong. Both note recurrent methodological issues: small trials, short duration, inconsistent extract standardization, heterogeneity in primary outcomes, and inconsistent reporting of randomization and blinding.

Safety

Ginseng is generally well tolerated in trials of ≤ 12 weeks. The 2021 Cochrane review of ED found risk ratio for adverse events 1.45 (95% CI: 0.69–3.03; low-certainty), interpreted as little to no difference vs. placebo.¹¹ Across the broader systematic reviews, reported adverse events are typically mild and self-limited (gastrointestinal upset, headache, insomnia, nervousness).¹⁴

Pharmacological concerns warranting clinical attention:

• Warfarin: case reports document INR shifts in either direction. Mechanism is incompletely characterized; a CYP-mediated explanation is plausible. Concomitant use is best avoided or monitored. Discussion in the broader RCT review.¹⁴
• Hypoglycemic agents: the small but reproducible glucose-lowering signal in the Shishtar review⁴ suggests potential additive effect with sulfonylureas, insulin, or GLP-1 agonists; clinical magnitude is small but nontrivial in already-controlled patients.
• CYP3A4 substrates: ginsenosides have shown CYP3A4 modulation in non-clinical models; clinical consequence in dosed humans is uncertain.
• Pregnancy and pediatric populations: evidence base is thin; precautionary avoidance in pregnancy is the conventional position.

Long-term (> 6 months) safety data is sparse across all systematic reviews; the field has prioritized efficacy questions over chronic-exposure safety.

Classical context

In classical Chinese materia medica, rén shēn (人参) is the prototypical qi-tonifying herb, prescribed for what classical authors describe as deficiency states presenting with fatigue, weak voice, sweating, and pulse weakness. The Shénnóng Běncǎo Jīng (compiled c. 200 CE; the foundational materia medica) classifies it among the superior-grade tonics; the Bencao Gangmu (Li Shizhen, 1578) consolidates and expands the earlier indications. Modern evidence converges most clearly with the classical “fatigue” indication and least clearly with broader claims of qi-tonification, life-extension, or general wellness benefit. The classical framework predates randomized controlled methodology by approximately two millennia and is included here as historical context, not as an evidence source — classical references are not listed in this article’s citations[] (which is reserved for DOI-bearing modern literature).

Open questions

Five empirical questions remain underexplored and would each materially advance the field:

1. Bioavailability-stratified efficacy. Do trials that genotype or otherwise characterize gut-microbiome-driven Compound K production show larger and more consistent clinical effects than trials that do not? The pharmacokinetic literature predicts yes; no trial has tested it.
2. Long-term glycemic effect. Does the small fasting-glucose reduction observed in 6–12 week trials persist at 6–12 months? No published RCT has tested ginseng for diabetes prevention or maintenance over a year or more.
3. Cognition in cognitive impairment. The 2010 Cochrane review identified one cognitive-impairment trial; the field has not produced a high-quality follow-up. A modern, adequately powered RCT in mild cognitive impairment or early dementia would be informative regardless of outcome.
4. CRF mechanism. Is the small CRF signal mediated by HPA-axis modulation, anti-inflammatory effects, or symptom-attribution rather than fatigue per se? Trials reporting only patient-reported outcome scales cannot distinguish.
5. Standardization-stratified pooling. Pooled effect sizes are dragged down by trials using non-standardized preparations. Sub-analyses restricted to extracts at fixed ginsenoside standardization (e.g. 4–7%) may yield substantially different point estimates; this analysis has been called for but not systematically performed.

References

Footnotes

1. Sharma A, Lee HJ. Ginsenoside Compound K: insights into recent studies on pharmacokinetics and health-promoting activities. Biomolecules (2020). DOI: 10.3390/biom10071028. ↩ ↩²

2. Won HJ, Kim HI, Park T, et al. Non-clinical pharmacokinetic behavior of ginsenosides. Journal of Ginseng Research (2019). DOI: 10.1016/j.jgr.2018.06.001. ↩

3. Wang Y, Mou C, Hu Y, et al. In-vivo metabolism, pharmacokinetics, and pharmacological activities of ginsenosides from ginseng. Journal of Ginseng Research (2025). DOI: 10.1016/j.jgr.2025.05.003. ↩ ↩²

4. Shishtar E, Sievenpiper JL, Djedovic V, et al. The effect of ginseng (the genus Panax) on glycemic control: a systematic review and meta-analysis of randomized controlled clinical trials. PLoS ONE (2014). DOI: 10.1371/journal.pone.0107391. ↩ ↩² ↩³

5. Jafari A, Mardani H, Abbastabar M, et al. The effect of ginseng supplementation on cardiovascular disease risk factors: a comprehensive systematic review and dose-response meta-analysis. British Journal of Nutrition (2025). DOI: 10.1017/S0007114525103607. ↩

6. Bach HV, Kim J, Myung SK, Cho YA. Efficacy of ginseng supplements on fatigue and physical performance: a meta-analysis. Journal of Korean Medical Science (2016). DOI: 10.3346/jkms.2016.31.12.1879. ↩

7. Zhu J, Xu X, Zhang X, et al. Efficacy of ginseng supplements on disease-related fatigue: a systematic review and meta-analysis. Medicine (Baltimore) (2022). DOI: 10.1097/MD.0000000000029767. ↩

8. Li X, Yang M, Zhang YL, et al. Ginseng and ginseng herbal formulas for symptomatic management of fatigue: a systematic review and meta-analysis. Journal of Integrative and Complementary Medicine (2023). DOI: 10.1089/jicm.2022.0532. ↩

9. Luo WT, Huang TW. Effects of ginseng on cancer-related fatigue: a systematic review and meta-analysis of randomized controlled trials. Cancer Nursing (2023). DOI: 10.1097/NCC.0000000000001068. ↩

10. Geng J, Dong J, Ni H, et al. Ginseng for cognition. Cochrane Database of Systematic Reviews (2010). DOI: 10.1002/14651858.CD007769.pub2. ↩

11. Lee HW, Lee MS, Kim TH, et al. Ginseng for erectile dysfunction. Cochrane Database of Systematic Reviews (2021). DOI: 10.1002/14651858.CD012654.pub2. ↩ ↩²

12. Borrelli F, Colalto C, Delfino DV, et al. Herbal dietary supplements for erectile dysfunction: a systematic review and meta-analysis. Drugs (2018). DOI: 10.1007/s40265-018-0897-3. ↩

13. Jang DJ, Lee MS, Shin BC, et al. Red ginseng for treating erectile dysfunction: a systematic review. British Journal of Clinical Pharmacology (2008). DOI: 10.1111/j.1365-2125.2008.03236.x. ↩

14. Shergis JL, Zhang AL, Zhou W, Xue CC. Panax ginseng in randomised controlled trials: a systematic review. Phytotherapy Research (2013). DOI: 10.1002/ptr.4832. ↩ ↩² ↩³

15. Choi J, Kim TH, Choi TY, Lee MS. Ginseng for health care: a systematic review of randomized controlled trials in Korean literature. PLoS ONE (2013). DOI: 10.1371/journal.pone.0059978. ↩